
Naloxone is a critical tool in addressing opioid overdoses and today’s approval underscores the extensive efforts the agency has undertaken to combat the overdose crisis.
Director of the FDA’s Center for Drug Evaluation and Research, Dr. Patrizia Cavazzoni. The FDA announced the approval of an over-the-counter nasal spray that helps prevent fatal opioid overdoses.
Why It Matters: The Food and Drug Administration approved the use of over-the-counter Naloxone Nasal Spray, which helps reverse deadly overdoses of opioids (such as fentanyl, which is 50x "more powerful than heroin") when used as directed. Similar medicine has been available by prescription only, but the announcement makes the nasal spray available at convenience stores, supermarkets, gas stations, etc., and is expected to be on shelves around late summer.
Big Picture: The opioid epidemic was declared a public health emergency in 2017 and is renewed every 90 days. Between October 2021 and October 2022, more than 101,750 people died from a drug overdose – which is more than motor vehicle traffic deaths and firearm deaths combined during 2021, according to data from the CDC. The FDA's approval of the nasal spray is intended to decrease the number of overdoses, particularly combatting the rising rate of opioid-related deaths.
For the full FDA announcement: FDA Approves First Over-the-Counter Naloxone Nasal Spray
FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal spray (CNBC)
by Jenna Lee, Founder of SmartHER News




